89
Participants
Start Date
December 3, 2014
Primary Completion Date
August 3, 2016
Study Completion Date
August 3, 2016
AZD7986, oral solution, 1 to 50 mg/mL
Starting dose in single ascending dose part: 5 mg
Placebo, oral solution
Matching placebo
Research Site, Harrow
Lead Sponsor
AstraZeneca
INDUSTRY